Intranasal Live Attenuated RSV Vaccine Candidates for Infants Found Effective

Meissa Vaccines today announced interim clinical data of MV-012-968, an intranasal live attenuated RSV vaccine candidate, from a Phase 1c study in RSV-naïve (seronegative) infants and young children.

The study enrolled 66 participants between the ages of six and 36 months at multiple sites in the U.S. to evaluate the safety and immunogenicity of the needle-free, adjuvant-free MV-012-968 vaccine.

Meissa’s intranasal live attenuated RSV vaccine was well-tolerated with no safety concerns identified, no serious adverse events to date, and negligible vaccine virus shedding.

Solicited symptoms were generally mild and did not differ in incidence from the placebo group.

At the highest dose regimen studied to date (two doses of 106 PFU), the vaccine stimulated a serum-neutralizing antibody response in 78% of RSV-naïve children. T

Taken together with nasal IgA responses, the vaccine induced an immune response in 89% of RSV-naïve children.

“The development of a safe and effective RSV vaccine is a significant global health priority that could save thousands of lives and protect the health of millions of children around the world,” said Frank Glavin, CEO of Meissa Vaccines, in a press release on November 7, 2022.

“The clinical data we have generated from both our RSV and COVID-19 programs demonstrate the enormous potential of Meissa’s AttenuBlock platform to develop safe and effective intranasal live attenuated vaccines to protect against serious respiratory viruses, and we look forward to continuing to advance our vaccine candidates in clinical trials.”

Additional RSV vaccine and antibody development news are posted at PrecisionVaccinations.com/RSV.